ALFA Finder| Metric | H2 FY26 | H1 FY26 | H2 FY25 |
|---|---|---|---|
| Revenue from operations | 32.6 | 9.7 | 10.3 |
| Other income | 0.0 | 0.0 | 0.3 |
| Total income | 32.6 | 9.7 | 10.6 |
| Profit before exceptional items & tax | 2.6 | 0.2 | 0.2 |
| Profit before tax | 2.6 | 0.2 | 0.2 |
| Net profit | 1.8 | 0.2 | 0.1 |
| Operating margin | 8.0% | 2.1% | 1.9% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +1700.00% |
|---|---|
| Net profit, quarter on quarter | +800.00% |
| Revenue, year on year | +216.50% |
NSE results filing, NSE: VILINBIO. Figures extracted from the filing.
Vilin Bio Med Ltd: key numbers
- Share price
- ₹52.00
- Market cap
- ₹79.30 Cr
- Revenue (annual)
- ₹42.26 Cr
- Net profit (annual)
- ₹1.93 Cr
- P/E (TTM)
- 41.1×Sector 43.8×
- Promoter holding
- 56.65%+0.00% QoQ
- FII holding
- 0.13%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Vilin Bio Med Ltd
All →Vilin Bio Med Other Announcement
Vilin Bio Med voluntarily filed its Integrated Corporate Governance Report for the quarter ended September 30, 2026, despite being exempt as an NSE Emerge listed entity. No material business transaction or decision is disclosed.
Vilin Bio Med Acquisition
Vilin Bio Med held NCLT-convened meetings to approve a scheme of amalgamation with Chemgenix Laboratories. Voting results remain pending in the Scrutinizer's report.
Vilin Bio Med Merger & Restructuring
Vilin Bio Med Limited announced an NCLT-convened meeting on October 15, 2026, to vote on a Scheme of Arrangement with Chemgenix Laboratories Private Limited.
Vilin Bio Med Board Meeting Date
Vilin Bio Med Limited scheduled a board meeting for September 18, 2026, to consider an amalgamation proposal. Trading window remains closed until September 20, 2026.
Vilin Bio Med Acquisition
Vilin Bio Med disclosed NCLT Hyderabad allowed its amalgamation with Chemgenix Laboratories Pvt Ltd. The order directs convening shareholder and creditor meetings for both companies.
Vilin Bio Med Annual General Meeting
Vilin Bio Med Limited conducted its 20th Annual General Meeting on September 2, 2026, to discuss financial statements, director appointments, and related party transactions.